Cronos Group Inc (CRON)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.24B
Last updated: Nov 17, 2026 at 11:04 AM ET
Cronos Group Inc (CRON) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Cronos Group reported EPS of $0.04, above the $0.03 estimate. It beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CRON's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
CRON Earnings Call
The latest CRON earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 37 quarters below that had an estimate, CRON beat 13, missed 19 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $83.90M, up 71.8% from $48.83M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.04 | $0.03 | $0.03 - $0.07 | +33.33% | Beat | -60.0% | 3 | 0 up, 1 down | Nov 5, 2026 | $83.90M |
| Jun 30, 2026 | $0.03 | $0.01 | $0.01 - $0.01 | +200.00% | Beat | N/A | 2 | 0 up, 1 down | Aug 6, 2026 | $53.01M |
| Mar 31, 2026 | $0.05 | $0.01 | $0.00 - $0.01 | +400.00% | Beat | +66.7% | 2 | 0 up, 1 down | May 11, 2026 | $45.21M |
| Dec 31, 2025 | $0.00 | $0.01 | $0.01 - $0.03 | -147.00% | Miss | -103.0% | 3 | 0 up, 0 down | Feb 26, 2026 | $32.04M |
| Sep 30, 2025 | $0.10 | $0.02 | N/A | +400.00% | Beat | +233.3% | 1 | 0 up, 0 down | Nov 6, 2025 | $48.83M |
| Jun 30, 2025 | -$0.10 | -$0.02 | N/A | -400.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 7, 2025 | $33.45M |
| Mar 31, 2025 | $0.03 | $0.00 | N/A | +957.14% | Beat | N/A | N/A | 0 up, 0 down | May 8, 2025 | $32.26M |
| Dec 31, 2024 | $0.16 | -$0.01 | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Feb 27, 2025 | $30.30M |
| Sep 30, 2024 | $0.03 | -$0.01 | -$0.02 - $0.00 | +400.00% | Beat | N/A | 3 | 0 up, 0 down | Nov 12, 2024 | $34.26M |
| Jun 30, 2024 | -$0.02 | -$0.07 | N/A | +71.43% | Beat | N/A | 4 | 0 up, 0 down | Aug 8, 2024 | $27.76M |
| Mar 31, 2024 | -$0.01 | -$0.01 | -$0.02 - -$0.01 | 0.00% | In line | N/A | 3 | 0 up, 0 down | May 9, 2024 | $25.29M |
| Dec 31, 2023 | -$0.05 | -$0.01 | -$0.02 - -$0.01 | -400.00% | Miss | N/A | 2 | 0 up, 0 down | Feb 29, 2024 | $23.91M |
| Sep 30, 2023 | -$0.02 | -$0.04 | N/A | +50.00% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2023 | $24.81M |
| Jun 30, 2023 | -$0.03 | -$0.05 | -$0.05 - -$0.02 | +40.00% | Beat | N/A | 5 | 0 up, 0 down | Aug 8, 2023 | $19.02M |
| Mar 31, 2023 | -$0.03 | -$0.05 | -$0.07 - -$0.02 | +40.00% | Beat | N/A | 4 | 0 up, 0 down | May 9, 2023 | $19.50M |
| Dec 31, 2022 | -$0.21 | -$0.05 | -$0.07 - -$0.03 | -320.00% | Miss | N/A | 4 | 0 up, 0 down | Feb 28, 2023 | $19.70M |
| Sep 30, 2022 | -$0.09 | -$0.07 | -$0.07 - -$0.04 | -28.57% | Miss | -142.9% | 4 | 1 up, 0 down | Nov 7, 2022 | $20.41M |
| Jun 30, 2022 | -$0.07 | -$0.07 | -$0.07 - -$0.03 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Aug 9, 2022 | $21.60M |
| Mar 31, 2022 | -$0.11 | -$0.10 | N/A | -10.00% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2022 | $25.03M |
| Dec 31, 2021 | -$0.11 | -$0.13 | N/A | +15.38% | Beat | N/A | 3 | 2 up, 0 down | Feb 18, 2022 | $15.92M |
| Sep 30, 2021 | $0.21 | -$0.10 | -$0.12 - -$0.10 | +310.00% | Beat | N/A | 4 | 0 up, 0 down | Sep 30, 2021 | $20.41M |
| Jun 30, 2021 | -$0.14 | -$0.08 | N/A | -75.00% | Miss | N/A | N/A | N/A | Aug 6, 2021 | $15.62M |
| Mar 31, 2021 | -$0.14 | -$0.11 | N/A | -27.27% | Miss | N/A | N/A | N/A | May 7, 2021 | $12.61M |
| Dec 31, 2020 | -$0.31 | -$0.07 | N/A | -342.86% | Miss | -247.6% | N/A | N/A | Feb 26, 2021 | $24.68M |
| Sep 30, 2020 | -$0.13 | -$0.05 | N/A | -160.00% | Miss | N/A | N/A | N/A | Nov 5, 2020 | $11.36M |
| Jun 30, 2020 | -$0.09 | -$0.07 | N/A | -28.57% | Miss | N/A | N/A | N/A | Aug 6, 2020 | $9.88M |
| Mar 31, 2020 | -$0.10 | -$0.09 | N/A | -11.11% | Miss | N/A | N/A | N/A | May 8, 2020 | $8.43M |
| Dec 31, 2019 | $0.21 | -$0.04 | N/A | +625.00% | Beat | N/A | N/A | N/A | Mar 30, 2020 | $7.92M |
| Sep 30, 2019 | -$0.07 | -$0.04 | N/A | -75.00% | Miss | N/A | N/A | N/A | Nov 12, 2019 | $6.27M |
| Jun 30, 2019 | -$0.04 | -$0.02 | N/A | -100.00% | Miss | N/A | N/A | N/A | Aug 8, 2019 | $8.06M |
| Mar 31, 2019 | -$0.06 | -$0.03 | N/A | -100.00% | Miss | N/A | N/A | N/A | May 9, 2019 | $3.39M |
| Dec 31, 2018 | -$0.05 | $0.02 | N/A | -350.00% | Miss | N/A | N/A | N/A | Mar 26, 2019 | $3.71M |
| Sep 30, 2018 | -$0.04 | -$0.02 | N/A | -100.00% | Miss | N/A | N/A | N/A | Nov 13, 2018 | $2.91M |
| Jun 30, 2018 | -$0.02 | -$0.01 | N/A | -100.00% | Miss | N/A | N/A | N/A | Aug 14, 2018 | $2.58M |
| Mar 31, 2018 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | May 15, 2018 | $2.28M |
| Sep 30, 2017 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 29, 2017 | $1.31M |
| Jun 30, 2017 | -$0.01 | -$0.01 | N/A | 0.00% | In line | N/A | N/A | N/A | Aug 28, 2017 | $643000 |
| Mar 31, 2017 | -$0.02 | -$0.01 | N/A | -100.00% | Miss | N/A | N/A | N/A | May 1, 2017 | $514000 |
| Dec 31, 2016 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 17, 2017 | $1.97M |
| Sep 30, 2016 | $0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 30, 2016 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.03, down 84.1% from the year before. It was -$0.03 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.03 | -84.1% |
| Dec 31, 2024 | $0.16 | N/A |
| Dec 31, 2023 | -$0.13 | N/A |
| Dec 31, 2022 | -$0.48 | N/A |
| Dec 31, 2021 | -$0.18 | N/A |
| Dec 31, 2020 | -$0.63 | -1675.0% |
| Dec 31, 2019 | $0.04 | N/A |
| Dec 31, 2018 | -$0.16 | N/A |
| Dec 31, 2016 | -$0.03 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,646 | 7 | |
| 2026Q2 | Jun 30, 2026 | 3,242 | 8 | |
| 2025Q4 | Dec 31, 2025 | 4,184 | 8 | |
| 2025Q3 | Sep 30, 2025 | 2,146 | 5 | |
| 2025Q2 | Jun 30, 2025 | 1,764 | 4 | |
| 2025Q1 | Mar 31, 2025 | 2,402 | 5 | |
| 2024Q4 | Dec 31, 2024 | 2,608 | 4 | |
| 2024Q3 | Sep 30, 2024 | 3,025 | 6 |
2026Q3 Earnings Call
Opening remarks
Harrison Aaron Senior Director, Investor Relations and Corporate Development Thank you, Stephanie, and thank you for joining us today to review Cronos' 2026 Q3 financial and business performance. Today, I am joined by our Chairman, President, and CEO, Mike Gorenstein, and our CFO, Anna Shlimak. Cronos issued a news release announcing our financial results this morning, which is filed on our EDGAR and SEDAR profiles. This information and the prepared remarks will also be posted on our website under Investor Relations. Before I turn the call over to Mike, let me remind you that we may make forward-looking statements and refer to non-GAAP financial measures during this call. These forward-looking statements are based on management's current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings that are available on our website, by which any forward-looking statements made during this call are qualified in their entirety. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can also be found in the earnings materials that are available on our website. Lastly, we will be making statements regarding market share information throughout this conference call, and unless otherwise stated, all market share data is provided by HiFyre. We will now make prepared remarks, and then we'll move to a question-and-answer session. With that, I'll pass it over to Cronos' Chairman, President, and CEO, Mike Gorenstein.
Mike Gorenstein Chairman, President, and CEO Thanks, Harrison. Cronos delivered an outstanding third quarter, organically achieving records across net revenue, gross profit, and Adjusted EBITDA, reflecting the successful execution of our borderless product strategy across each region in which we operate. Starting with Israel, Cronos delivered its 11th consecutive quarter of record net revenue, growing 33% year-over-year, or 19% growth on a constant currency basis, with the PEACE NATURALS brand reinforcing its leadership position based on pharmacy data collected by Cronos. Our value brand, LIT, also drove growth in the quarter. Turning to Canada, we delivered record net revenue, with our brands generating 41% year-over-year retail sales growth relative to industry-wide sales growth of 1%. The Spinach brand posted another standout quarter, with its market-leading share gains underscoring the effectiveness of our innovation engine. In Canada, Spinach maintained its number one position in vapes for the third consecutive quarter, with total vape market share expanding to 11.4%. Within the vape cartridge subcategory, Spinach held its number one position for the fourth consecutive quarter, with market share expanding to 12.1%. In the all-in-one vape subcategory, Spinach share expanded to 10.2%, as our PUFFERZ all-in-one innovation continues to gain market traction.
Frequently Asked Questions About CRON
Did CRON beat earnings estimates last quarter?
Yes. Cronos Group reported EPS of $0.04 for the quarter ended Sep 30, 2026, above the $0.03 estimate, a 33.33% surprise.
What EPS do analysts expect from CRON next quarter?
The consensus EPS estimate for Cronos Group for the quarter ending Dec 31, 2026 is $0.04 from 5 analysts, with estimates from $0.03 to $0.05.
How often does CRON beat earnings estimates?
Cronos Group beat the EPS estimate in 6 of the 8 most recent quarters that had an estimate, with an average surprise of +230.43%.
CRON pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors